Ashley – a 36-year-old who has visited tanning salons since she was a teenager – discovered an unusual mole on her neck. When she visited the dermatologist, he removed the mole and determined that it was melanoma. The next step was to remove the lymph nodes and surrounding tissue to see if the melanoma had spread. It had. Following the pathology report, Ashley underwent interferon treatment for a year.
Ashley and her doctors were faced with a number of options during her course of treatment. Wide excision with lymph dissection was a certainty, but what combination of other therapies would produce the optimum long-term results: targeted therapy, immunotherapy, chemotherapy, immunotherapy combined with chemotherapy (biochemotherapy), and/or radiation. Perhaps she should consider a clinical trial.
Ashley, a new mom, was in this to win, so she wanted all the information she could get to help make this decision.
Using a CT scan, Analytic Morphomics can measure underlying health and the presence of sarcopenia or cachexia – keen predictors of poor outcomes and disease recurrence in melanoma < Read our published work here > . Understanding the biological response is important in controlling the spread of melanoma, and doctors can use this to predict the likelihood of the cancer spreading and determine the best holistic path forward.